REGULATED INFORMATIONPRESS RELEASE Transparency notifications pursuant to Article 14 of the Law of May 2, 2007 Leuven (Belgium) - January 16, 2018, 22:00h CET - TiGenix NV (Euronext Brussels and Nasdaq: TIG; "TiGenix") announced today that it received transparency not...Read More
PRESS RELEASE TiGenix announces publication in Gastroenterology of 52-week results of the Phase III ADMIRE-CD trial of Cx601 Leuven (BELGIUM) - January 15, 2018, 07:00 CET - TiGenix NV (Euronext Brussels and NASDAQ: TIG), an advanced biopharmaceutical company focused on exploitin...Read More
REGULATED INFORMATIONPRESS RELEASE Transparency notifications pursuant to Article 14 of the Law of May 2, 2007 Leuven (Belgium) - January 12, 2018, 22:00h CET - TiGenix NV (Euronext Brussels and Nasdaq: TIG; "TiGenix") announced today that it received transparency noti...Read More
PRESS RELEASEREGULATED INFORMATION Transparency Information Leuven (BELGIUM) - January 11, 2018, 22:00h CET - TiGenix NV (Euronext Brussels and Nasdaq: TIG) publishes information in accordance with articles 15 and 18 of the Belgian Law of May 2, 2007 regarding t...Read More
REGULATED INFORMATIONPRESS RELEASE Transparency notification pursuant to Article 14 of the Law of May 2, 2007 Leuven (Belgium) - January 3, 2018, 22:00h CEST - TiGenix NV (Euronext Brussels and Nasdaq: TIG; "TiGenix") publishes today a transparency notification pursuan...Read More
PRESS RELEASE TiGenix confirms strategic focus on Cx601 and its adipose derived stem cell (eASC) platform Leuven (BELGIUM) - December 20, 2017, 7:00h CET - TiGenix NV (Euronext Brussels and NASDAQ: TIG) ("TiGenix" or "the Company"), an advanced biopharmaceutic...Read More
PRESS RELEASE REGULATED INFORMATION INSIDE INFORMATION Takeda and TiGenix announce that Cx601 (darvadstrocel) has received a positive CHMP opinion to treat complex perianal fistulas in Crohn's disease &#x...Read More
PRESS RELEASE REGULATED INFORMATION INSIDE INFORMATION Mesoblast grants TiGenix an exclusive global patent license to use adipose-derived mesenchymal stem cells in the local treatment of fistulae New York, USA, Melbourne, Australia and Leuven, Belgium, December 15, 2017, 0...Read More
TSX.V: TIGOTCMKTS: TIGCFFrankfurt: 8N61 VANCOUVER, Dec. 11, 2017 /CNW/ - Triumph Gold Corp., (TSX-V: TIG) (OTCMKTS: TIGCF) ("Triumph Gold" or the "Company") is pleased to announce that its trading symbol on the OTCQB Venture Market has changed to TIGCF effective December 7,...Read More
TSX.V: TIGOTCMKTS: TIGCFFrankfurt: 8N61 VANCOUVER, Dec. 11, 2017 /PRNewswire/ - Triumph Gold Corp., (TSX-V: TIG) (OTCMKTS: TIGCF) ("Triumph Gold" or the "Company") is pleased to announce that its trading symbol on the OTCQB Venture Market has changed to TIGCF effective Decem...Read More
Leuven (Belgium) - November 24, 2017, 22:00h CEST -TiGenix NV (Euronext Brussels and Nasdaq: TIG; "TiGenix") publishes today a transparency notification pursuant to Article 14 of the Belgian Law of May 2, 2007 regarding the publication of major holdings in issuers whose securities a...Read More
TSX.V: TIGOTCMKTS: NFRGFFrankfurt: 8N61 VANCOUVER, Nov. 20, 2017 /PRNewswire/ - Triumph Gold Corp., (TSX-V: TIG) (OTCMKTS: NFRGF) ("Triumph Gold" or the "Company") is pleased to announce that recent soil sampling has defined a 1.8 X 0.75 km multi-element (Au, Cu, Pb, Zn, As,...Read More
PRESS RELEASE TiGenix to present positive 52-week Phase III Cx601 data at EHA-SWG Scientific Meeting Leuven (BELGIUM) - November 20, 2017, 07:00h CET - TiGenix NV (Euronext Brussels and NASDAQ: TIG), an advanced biopharmaceutical company focused on exploiting the anti-inflammatory properties o...Read More
TSX.V:TIGOTCMKTS: NFRGFFrankfurt: 8N61 VANCOUVER, Nov. 15, 2017 /PRNewswire/ - Triumph Gold Corp., (TSX-V: TIG) (OTCMKTS: NFRGF) ("Triumph Gold" or the "Company") is pleased to announce that exploration drilling in an underexplored portion of the Revenue soil anomaly intersected high-grade gol...Read More
PRESS RELEASE TiGenix announces approval of trade name for lead development candidate Cx601 in Europe International Nonproprietary Name (INN), darvadstrocel, approved for Cx601 Leuven (BELGIUM) - November 16, 2017, 7h:00 CET - TiGenix NV (Euronext Brussels and...Read More
PRESS RELEASE TiGenix announces partial conversion of bondsLeuven (BELGIUM) - November 6, 2017, 7:00h CET - TiGenix NV (Euronext Brussels and NASDAQ: TIG), an advanced biopharmaceutical company focused on exploiting the anti-inflammatory properties of allogeneic, or donor-derived, stem cells t...Read More
TSX.V: TIGOTCMKTS: NFRGF Frankfurt: 8N61 VANCOUVER, Nov. 2, 2017 /CNW/ - Triumph Gold Corp., (TSX-V: TIG) (OTCMKTS: NFRGF) ("Triumph Gold" or the "Company") is pleased to announce that prospecting and step out drilling to the east and west of the Revenue diatreme have been rewarded with signifi...Read More
TSX.V: TIGOTCMKTS: NFRGF Frankfurt: 8N61 VANCOUVER, Nov. 2, 2017 /PRNewswire/ - Triumph Gold Corp., (TSX-V: TIG) (OTCMKTS: NFRGF) ("Triumph Gold" or the "Company") is pleased to announce that prospecting and step out drilling to the east and west of the Revenue diatreme have been rewarded with...Read More
PRESS RELEASE TiGenix strengthens European IP protection around lead development program Cx601 Leuven (BELGIUM) - November 2, 2017, 07:00h CET - TiGenix NV (Euronext Brussels and NASDAQ: TIG), an advanced biopharmaceutical company focused on exploiting the anti-inflammatory properties of allogen...Read More
PRESS RELEASE TiGenix granted Orphan Drug Designation from the U.S. FDA for Cx601 Leuven (BELGIUM) - October 23, 2017, 7:00h CEST - TiGenix NV (Euronext Brussels and NASDAQ: TIG), an advanced biopharmaceutical company focused on exploiting the anti-inflammatory properties of allogeneic, or donor...Read More